【Zephyr AI 完成 1.1 亿美元 A 轮融资，引领精准医疗 AI 新篇章】
北京，中国 – 近日，全球医疗技术领域的创新力量Zephyr AI宣布，其在A轮融资中成功获得了1.11亿美元的巨额投资，这一消息在业界引起了广泛关注。本轮融资由知名投资机构Revolution Growth领投，同时获得了制药巨头礼来公司、社会企业家Jeff Skoll以及EPIQ Capital Group等重量级投资者的青睐。
Zephyr AI，一家专注于开发快速且可解释的人工智能解决方案的初创公司，其目标是推动精准医疗的发展，通过AI技术实现更高效、更个性化的医疗服务。此次融资的成功，不仅为Zephyr AI的进一步研发提供了充足的资金支持，也标志着其在精准医疗领域的领先地位得到了广泛认可。
据BusinessWire报道，Zephyr AI的AI算法已经在医疗数据分析和疾病预测方面展现出显著优势，其可解释性使得医疗专业人员能够更好地理解和信任这些技术，从而在临床实践中更有效地应用。礼来公司的参与投资，暗示了制药行业对AI在药物研发和患者管理中潜力的看好。
Zephyr AI的创始人兼首席执行官在声明中表示：“我们非常感谢投资方的信任和支持，这笔资金将加速我们的人工智能技术在医疗领域的应用，帮助医生提供更精准、更及时的诊断和治疗方案，最终改善患者的生活质量。”
此次融资事件预示着Zephyr AI将在精准医疗AI领域开启新的篇章，同时也为全球医疗健康行业带来了一场深度融合AI技术的革命。随着技术的不断进步，Zephyr AI有望引领医疗行业进入一个更加智能化、个性化的时代。
英语如下：
**News Title:** “Zephyr AI, a Precision Medicine Startup, Raises $110M in Series A Funding, Pioneering a New Era in AI-Driven Healthcare”
**Keywords:** Zephyr AI, Precision Medicine, Series A Funding
**News Content:**
**[Zephyr AI Secures $110M in Series A Financing, Forging a New Frontier in Precision Medicine AI]**
Beijing, China – Zephyr AI, a global innovator in the medical technology sector, recently announced it has successfully raised $110 million in a Series A funding round, drawing substantial attention from the industry. The round was led by prominent investment firm Revolution Growth, with participation from pharmaceutical giant Eli Lilly, social entrepreneur Jeff Skoll, and EPIQ Capital Group, among other influential investors.
Zephyr AI, a startup dedicated to developing fast and explainable artificial intelligence solutions, aims to advance precision medicine by leveraging AI to deliver more efficient and personalized healthcare services. This successful funding not only provides ample resources for the company’s ongoing research and development but also signifies a broad endorsement of its leading position in the precision medicine landscape.
According to BusinessWire, Zephyr AI’s AI algorithms have demonstrated notable advantages in medical data analysis and disease prediction, with their explainability fostering better understanding and trust among medical professionals, thus enabling more effective application in clinical settings. Eli Lilly’s investment signals the pharmaceutical industry’s optimism about AI’s potential in drug development and patient management.
The founder and CEO of Zephyr AI commented in a statement, “We are deeply grateful for our investors’ trust and support. This funding will accelerate the application of our AI technologies in healthcare, assisting doctors in providing more precise and timely diagnoses and treatments, ultimately enhancing patients’ quality of life.”
This funding event portends a new chapter for Zephyr AI in the precision medicine AI sector and ushers in a revolutionary integration of AI technology across the global healthcare industry. As technology progresses, Zephyr AI is poised to spearhead the industry into a more intelligent and personalized era.
【来源】https://www.businesswire.com/news/home/20240312475536/en/Zephyr-AI-Raises-111-Million-in-Series-A-Financing
Views: 1